Tag Archives: cardiovascular benefits

SGLT2 inhibitors exert their cardioprotective effect through several proposed mechanisms. Primarily, by inhibiting the SGLT2 in the proximal renal tubules, these agents promote urinary glucose excretion, leading to reductions in serum glucose levels, body weight, and blood pressure.1,2 Additionally, SGLT2 inhibitors are thought to drive cardiovascular benefits by promoting natriuresis and diuresis, reducing preload and afterload on the heart.1,2 They also appear to improve myocardial energetics, reduce oxidative stress and inflammation, and exert favourable effects on cardiac remodelling and vascular function.1,2 The DAPA-HF (Dapagliflozin a